EE520 Cost-Effectiveness of Tremelimumab Plus Durvalumab for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma in the United States
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.2283
https://www.valueinhealthjournal.com/article/S1098-3015(24)02497-5/fulltext
Title :
EE520 Cost-Effectiveness of Tremelimumab Plus Durvalumab for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)02497-5&doi=10.1016/j.jval.2024.03.2283
First page :
Section Title :
Open access? :
No
Section Order :
10274